KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,886,400 | -55.1% | 240,000 | -61.4% | 0.89% | -61.0% |
| Q4 2022 | $4,202,469 | -45.4% | 621,667 | +17.3% | 2.29% | -44.4% |
| Q3 2022 | $7,691,000 | -4.8% | 530,062 | -35.4% | 4.12% | -35.3% |
| Q2 2022 | $8,076,000 | -7.0% | 820,752 | +39.3% | 6.36% | +13.5% |
| Q1 2022 | $8,686,000 | +60.3% | 589,270 | +43.9% | 5.61% | +72.9% |
| Q4 2021 | $5,419,000 | +20.7% | 409,620 | +59.1% | 3.24% | +31.3% |
| Q3 2021 | $4,491,000 | +3.5% | 257,391 | +42.1% | 2.47% | -9.0% |
| Q2 2021 | $4,341,000 | – | 181,171 | – | 2.71% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $38,088,000 | 25.57% |
| VHCP Management III, LLC | 637,884 | $14,129,000 | 6.60% |
| Vivo Capital, LLC | 1,359,149 | $30,105,000 | 2.82% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $8,611,000 | 2.78% |
| VHCP Management II, LLC | 376,889 | $8,348,000 | 2.63% |
| Samsara BioCapital, LLC | 118,500 | $2,625,000 | 1.73% |
| ACUTA CAPITAL PARTNERS, LLC | 213,000 | $4,718,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 187,599 | $4,165,000 | 1.54% |
| Ghost Tree Capital, LLC | 300,000 | $6,645,000 | 1.38% |
| Eventide Asset Management | 1,500,000 | $33,225,000 | 1.01% |